- Event

Asceneuron to present a poster on the M1 PAM program

Asceneuron will present a poster on the M1 PAM program at the Society for Neuroscience (SfN) Annual Meeting 2016 on November 12-16, 2016 in San Diego, USA.

- Press releases

Asceneuron receives grant from The Michael J. Fox Foundation for Parkinson’s research

Asceneuron has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research for the further development of positive allosteric modulators of the M1 muscarinic acetylcholine receptor.

- Event

Meet Asceneuron at Bio-Europe 2016

Asceneuron to attend Bio-Europe partnering event on 7-9 November, 2016 in Cologne, Germany

- Event

Asceneuron to present at the 6th FTD UK Annual Meeting 2016

Asceneuron to present at the 6th FTD UK Annual Meeting 2016 on November 4, 2016 in Cambridge, United Kingdom.

- Event

International Conference on Alzheimer’s Drug Discovery

Asceneuron to present at the 17th International Conference on Alzheimer’s Drug Discovery on 12-13 September, 2016 in Jersey City, NJ, USA

- Event

10th International Conference on Frontotemporal Dementias

Asceneuron to take part in a panel discussion on clinical trials at the 10th International Conference on Frontotemporal Dementias on August 31 - September 2, 2016, in Munich, Germany

- Event

1st European Conference on Drug Discovery for Neurodegeneration

Asceneuron to present at the 1st European Conference on Drug Discovery for Neurodegeneration on 15-17 May, 2016 in Budapest, Hungary

- Press releases

Asceneuron appoints Hans Schikan as Chairman to the Board of Directors

Asceneuron today announced the appointment of Hans Schikan (PharmD) as Non-Executive Chairman to the Board of Directors.

- News

"A l'EPFL, Asceneuron lève 30 millions" (Article in Le Matin Dimanche)

- Press releases

Asceneuron raises CHF 30 million

Asceneuron today announced the closing of a Series A financing of CHF 30 million (USD 30.6 million). The financing round was led by Sofinnova Partners which becomes the largest financial investor in the company. They are joined by new investors SR One, Kurma Partners and Johnson &
Johnson Innovation – JJDC, Inc. (JJDC). The company’s founding investors MS Ventures also participated.